AAstrom Biosciences Inc
Business Identifier: autologous stem cell products for use in regenerative medicine
Public Profile:
Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company's autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use. Its clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and DCM development program, which is in Phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. Phase II trials investigating surgical and catheter-based delivery for its product in the treatment of DCM.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Clinical Human Cell Production System for Broad Use
Clinical-scale Production of Osteoprogenitor Cells
Automated Perfused Culture Process for Adult Stem Cells
Bioreactor for Enhanced T-cell Based Therapy of Melanoma
Dendritic Cell Subset for Enhanced Cancer Vaccine